Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Lixisenatide for the treatment of type 2 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{fda16d4a034541d9a256b856b629b9a1,
title = "Lixisenatide for the treatment of type 2 diabetes",
abstract = "Lixisenatide (trade name Lyxumia{\textregistered}), a short-acting glucagon-like peptide 1 receptor (GLP-1R) agonist, was approved for the treatment of type 2 diabetes by the European Medicines Agency in early 2013. In preclinical investigations, acceptable toxicity and carcinogenicity profiles were demonstrated, as well as pancreatic beta cell-preserving actions and favorable effects on glycemic control. Following subcutaneous administration in humans, lixisenatide displays linear pharmacokinetics and an absorption-dependent elimination half-life of 2-3 hours. In clinical trials of up to 1 year duration in patients with type 2 diabetes, treatment with lixisenatide alone and in combination with insulin and various oral antidiabetics conferred significant reductions in HbA1c, fasting and postprandial plasma glucose. In direct comparison with the other GLP-1R agonists on the market (exenatide and liraglutide), lixisenatide appears to be less efficient, or at best non-inferior in terms of reducing HbA1c, fasting plasma glucose and body weight. Nevertheless, lixisenatide confers fewer adverse events than the other currently marketed GLP-1R agonists, while exhibiting a clinically valuable effect on postprandial hyperglycemia.",
keywords = "Animals, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Drug Interactions, Half-Life, Humans, Hypoglycemic Agents, Peptides",
author = "Petersen, {A B} and Knop, {F K} and M Christensen",
note = "Copyright 2013 Prous Science, S.A.U. or its licensors. All rights reserved.",
year = "2013",
month = sep,
doi = "10.1358/dot.2013.49.9.2020940",
language = "English",
volume = "49",
pages = "537--53",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "9",

}

RIS

TY - JOUR

T1 - Lixisenatide for the treatment of type 2 diabetes

AU - Petersen, A B

AU - Knop, F K

AU - Christensen, M

N1 - Copyright 2013 Prous Science, S.A.U. or its licensors. All rights reserved.

PY - 2013/9

Y1 - 2013/9

N2 - Lixisenatide (trade name Lyxumia®), a short-acting glucagon-like peptide 1 receptor (GLP-1R) agonist, was approved for the treatment of type 2 diabetes by the European Medicines Agency in early 2013. In preclinical investigations, acceptable toxicity and carcinogenicity profiles were demonstrated, as well as pancreatic beta cell-preserving actions and favorable effects on glycemic control. Following subcutaneous administration in humans, lixisenatide displays linear pharmacokinetics and an absorption-dependent elimination half-life of 2-3 hours. In clinical trials of up to 1 year duration in patients with type 2 diabetes, treatment with lixisenatide alone and in combination with insulin and various oral antidiabetics conferred significant reductions in HbA1c, fasting and postprandial plasma glucose. In direct comparison with the other GLP-1R agonists on the market (exenatide and liraglutide), lixisenatide appears to be less efficient, or at best non-inferior in terms of reducing HbA1c, fasting plasma glucose and body weight. Nevertheless, lixisenatide confers fewer adverse events than the other currently marketed GLP-1R agonists, while exhibiting a clinically valuable effect on postprandial hyperglycemia.

AB - Lixisenatide (trade name Lyxumia®), a short-acting glucagon-like peptide 1 receptor (GLP-1R) agonist, was approved for the treatment of type 2 diabetes by the European Medicines Agency in early 2013. In preclinical investigations, acceptable toxicity and carcinogenicity profiles were demonstrated, as well as pancreatic beta cell-preserving actions and favorable effects on glycemic control. Following subcutaneous administration in humans, lixisenatide displays linear pharmacokinetics and an absorption-dependent elimination half-life of 2-3 hours. In clinical trials of up to 1 year duration in patients with type 2 diabetes, treatment with lixisenatide alone and in combination with insulin and various oral antidiabetics conferred significant reductions in HbA1c, fasting and postprandial plasma glucose. In direct comparison with the other GLP-1R agonists on the market (exenatide and liraglutide), lixisenatide appears to be less efficient, or at best non-inferior in terms of reducing HbA1c, fasting plasma glucose and body weight. Nevertheless, lixisenatide confers fewer adverse events than the other currently marketed GLP-1R agonists, while exhibiting a clinically valuable effect on postprandial hyperglycemia.

KW - Animals

KW - Blood Glucose

KW - Body Weight

KW - Diabetes Mellitus, Type 2

KW - Drug Evaluation, Preclinical

KW - Drug Interactions

KW - Half-Life

KW - Humans

KW - Hypoglycemic Agents

KW - Peptides

U2 - 10.1358/dot.2013.49.9.2020940

DO - 10.1358/dot.2013.49.9.2020940

M3 - Journal article

C2 - 24086950

VL - 49

SP - 537

EP - 553

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 9

ER -

ID: 41954506